Immunology

Alumis secures $259m to develop therapies for immune dysfunction

Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral…

Shifting the paradigm – novel approaches to amyotrophic lateral sclerosis therapy

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a swiftly advancing, fatal neurodegenerative condition marked by muscle…

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

AbbVie has signed a partnership and licensing agreement with OSE Immunotherapeutics for the latter’s monoclonal antibody OSE-230 in a deal…

AbbVie and Tentarix enter biologic development deal

AbbVie has signed a strategic partnership agreement with Tentarix Biotherapeutics to discover and develop new conditionally active, multi-specific biologic candidates…

Xyphos and Kelonia link for immuno-oncology drug development

Astellas subsidiary Xyphos Biosciences has entered a research partnership and licence agreement with Kelonia Therapeutics aimed at developing new immuno-oncology…

Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan

Swedish biotech Vicore Pharma has entered an exclusive licensing agreement for the Japanese rights for its idiopathic pulmonary fibrosis (IPF)…

China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor

The China National Medical Products Administration (NMPA) has granted clearance for the IND application of Guangzhou Fermion Technology’s FZ007-119. This…

AnaMar secures double orphan drug designation for systemic sclerosis drug

AnaMar has received orphan drug designations for its systemic sclerosis candidate AM1476 from the FDA and the EMA. The Swedish…

Inmagene to secure licence for two HUTCHMED drug candidates

Inmagene Biopharmaceuticals has exercised its option to secure an exclusive global and royalty-bearing licence for two HUTCHMED drug candidates, IMG-007…

Sanofi backs development of Graviton’s treatments for serious diseases

Graviton Bioscience has secured a strategic investment from Sanofi to develop a selective Rho/Rho-associated coiled coil [a structural motif in…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close